Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
VOR
$16.645
$
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Next Earnings
2026-02-25
Beta
2.023
Average Volume
Market Cap
Last Dividend
CIK
0001817229
ISIN
US9290332074
CUSIP
929033207
CEO
Jean-Paul Kress
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
159
IPO Date
2021-02-05
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference | BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston, MA. Presentation: Monday, March 2, 2026 at 9:50am – 10:20 am ETLocation: Regis A live webcast and archived replay of the presentation will be remain available for a period of 90 days on the Company's website at: https://ir.vorbio.com/events-presentations/ About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. | GlobeNewsWire | 2026-02-23 08:00:00 |
| Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of “Moderate Buy” from Brokerages | Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) has received an average recommendation of "Moderate Buy" from the fourteen brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, seven have given a buy recommendation and one has assigned a strong | Defense World | 2026-01-21 03:16:51 |
| Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference | BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. | GlobeNewsWire | 2026-01-06 08:00:00 |
| Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors | BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company's recently announced $150M PIPE financing, which included participation from both investors. | GlobeNewsWire | 2025-12-23 16:01:00 |
| Vor Bio Announces $150 Million Private Placement | BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $150 million, before deducting any offering-related expenses. Vor Bio did not engage a placement agent in connection with the private placement. The private placement is expected to close on or about December 18, 2025, subject to the satisfaction of customary closing conditions. | GlobeNewsWire | 2025-12-15 08:00:00 |
| Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of “Hold” from Brokerages | Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) has been given a consensus rating of "Hold" by the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, four have issued a buy recommendation and | Defense World | 2025-12-02 02:14:48 |
| Reviewing Vor Biopharma (NASDAQ:VOR) and Liminatus Pharma (NASDAQ:LIMN) | Vor Biopharma (NASDAQ: VOR - Get Free Report) and Liminatus Pharma (NASDAQ: LIMN - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership. Earnings and Valuation This table compares Vor | Defense World | 2025-11-29 01:12:49 |
| Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know | Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | Zacks Investment Research | 2025-11-25 13:00:37 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| 424B3 | 2026-02-05 | 2026-02-05 | View Filing |
| SC 13G/A | 2026-02-05 | 2026-02-05 | View Filing |
| EFFECT | 2026-02-04 | 2026-02-05 | View Filing |
| S-3 | 2026-01-29 | 2026-01-29 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2026-01-02 | 2026-01-02 | View Filing |
| SC 13D | 2025-12-23 | 2025-12-23 | View Filing |
| 4 | 2025-12-19 | 2025-12-19 | View Filing |
| 4 | 2025-12-19 | 2025-12-19 | View Filing |
| 4 | 2025-12-19 | 2025-12-19 | View Filing |
| 3 | 2025-12-19 | 2025-12-19 | View Filing |
| 3 | 2025-12-19 | 2025-12-19 | View Filing |
| SC 13G | 2025-12-19 | 2025-12-19 | View Filing |
| SC 13D/A | 2025-12-18 | 2025-12-18 | View Filing |
| 8-K | 2025-12-18 | 2025-12-18 | View Filing |
| SC 13G | 2025-12-17 | 2025-12-17 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 8-K | 2025-12-09 | 2025-12-09 | View Filing |
| 424B3 | 2025-12-01 | 2025-12-01 | View Filing |
| SC 13G | 2025-11-18 | 2025-11-18 | View Filing |
| SC 13D/A | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 424B5 | 2025-11-12 | 2025-11-12 | View Filing |
| 424B5 | 2025-11-10 | 2025-11-10 | View Filing |
| S-3/A | 2025-11-10 | 2025-11-10 | View Filing |
| SC 13G | 2025-11-07 | 2025-11-07 | View Filing |
| SC 13G | 2025-11-05 | 2025-11-05 | View Filing |
| 8-K | 2025-11-03 | 2025-11-03 | View Filing |
| SC 13D/A | 2025-10-30 | 2025-10-30 | View Filing |
| 4 | 2025-10-30 | 2025-10-30 | View Filing |
| 8-K | 2025-10-28 | 2025-10-28 | View Filing |
| SC 13D/A | 2025-10-27 | 2025-10-27 | View Filing |
| 4 | 2025-10-27 | 2025-10-27 | View Filing |
| 4 | 2025-10-22 | 2025-10-22 | View Filing |
| 4 | 2025-10-21 | 2025-10-21 | View Filing |
| SC 13D/A | 2025-10-20 | 2025-10-20 | View Filing |
| SC 13D/A | 2025-10-17 | 2025-10-17 | View Filing |
| 4 | 2025-10-17 | 2025-10-17 | View Filing |
| 4 | 2025-10-17 | 2025-10-17 | View Filing |
| SC 13D/A | 2025-10-16 | 2025-10-16 | View Filing |
| 4 | 2025-10-15 | 2025-10-15 | View Filing |
| SC 13D/A | 2025-10-10 | 2025-10-10 | View Filing |
| 4 | 2025-10-10 | 2025-10-10 | View Filing |
| SC 13D/A | 2025-10-08 | 2025-10-08 | View Filing |
| 4 | 2025-10-08 | 2025-10-08 | View Filing |
| SC 13D/A | 2025-10-06 | 2025-10-06 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| SC 13G | 2025-09-26 | 2025-09-26 | View Filing |
| SC 13G | 2025-09-25 | 2025-09-25 | View Filing |
| S-8 | 2025-09-24 | 2025-09-24 | View Filing |
| S-3 | 2025-09-24 | 2025-09-24 | View Filing |
| SC 13G | 2025-09-23 | 2025-09-23 | View Filing |
| 4 | 2025-09-22 | 2025-09-22 | View Filing |
| SC 13D/A | 2025-09-19 | 2025-09-19 | View Filing |
| 4 | 2025-09-18 | 2025-09-18 | View Filing |
| 8-K | 2025-09-17 | 2025-09-17 | View Filing |
| 4 | 2025-09-15 | 2025-09-15 | View Filing |
| SC 13D/A | 2025-09-12 | 2025-09-12 | View Filing |
| 4 | 2025-09-10 | 2025-09-10 | View Filing |
| 4 | 2025-09-10 | 2025-09-10 | View Filing |
| 4 | 2025-09-10 | 2025-09-10 | View Filing |
| SC 13D/A | 2025-09-09 | 2025-09-09 | View Filing |
| 3 | 2025-09-08 | 2025-09-08 | View Filing |
| 4 | 2025-09-05 | 2025-09-05 | View Filing |
| 8-K | 2025-09-02 | 2025-09-02 | View Filing |
| SC 13D/A | 2025-08-29 | 2025-08-29 | View Filing |
| 4 | 2025-08-29 | 2025-08-29 | View Filing |
| 4 | 2025-08-27 | 2025-08-27 | View Filing |
| 8-K | 2025-08-27 | 2025-08-27 | View Filing |
| 8-K | 2025-08-27 | 2025-08-27 | View Filing |
| 424B5 | 2025-08-27 | 2025-08-27 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| DEF 14A | 2025-08-08 | 2025-08-08 | View Filing |
| SC 13G/A | 2025-08-06 | 2025-08-06 | View Filing |
| 4 | 2025-07-30 | 2025-07-30 | View Filing |
| 3 | 2025-07-30 | 2025-07-30 | View Filing |
| PRE 14A | 2025-07-29 | 2025-07-29 | View Filing |
| 8-K | 2025-07-22 | 2025-07-22 | View Filing |
| 4 | 2025-07-18 | 2025-07-18 | View Filing |
| 4 | 2025-07-18 | 2025-07-18 | View Filing |
| 3 | 2025-07-18 | 2025-07-18 | View Filing |
| 3 | 2025-07-18 | 2025-07-18 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| 3 | 2025-07-10 | 2025-07-10 | View Filing |
| 8-K | 2025-07-10 | 2025-07-10 | View Filing |
| SC 13D/A | 2025-07-09 | 2025-07-09 | View Filing |
| SC 13D/A | 2025-06-27 | 2025-06-27 | View Filing |
| 4 | 2025-06-27 | 2025-06-27 | View Filing |
| 3 | 2025-06-27 | 2025-06-27 | View Filing |
| 8-K | 2025-06-26 | 2025-06-25 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Triple MA | 27.70% | 0.98 | 10 | 0.85 | 1.44 | 32.08 |
| Liquidity Sweep Strategy | 26.05% | 0.94 | 6 | 0.34 | 0.23 | 30.43 |
| Neural Forcast | 25.49% | 1.12 | 20 | 0.81 | 1.81 | 29.87 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxxx |
| xxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | x | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |